acetyl- cysteine effect in stroke treatment
Not Applicable
Recruiting
- Conditions
- Stroke.Vascular syndromes of brain in cerebrovascular disease
- Registration Number
- IRCT2017011931229N2
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
all admitted patients with first attack of mild to moderate CVA according to NIHSS between 0-16; admitted patients within first 24 hours of onset of CVA.
Exclusion criteria:Hemorrhagic stroke; Severe Hepatic or renal failure. ( creatinine clearance less than 30 mg/dl); History of Vasculitis; Allergy to N- acetyl- cystein; Alzheimer or dementia due to any cause; Coexistent other neurologic disorders.;Past history of CVA;Age more than 80 years; Diseases that affect on MMP-9 level. e.g neuropsychiatric disorders like schizophrenia and bipolar disorder,epilepsy and mutiple sclerosis; Intravenous or intaarterial r-tPA injection.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method MMP9. Timepoint: Before and 24 hours after intervention. Method of measurement: ELISA kit.;NIHSS. Timepoint: Before intervention, 24 hours, 2 weeks, 1 month and 3 months after intervention. Method of measurement: Standard scale.
- Secondary Outcome Measures
Name Time Method Side effects. Timepoint: 24 hours after treatment. Method of measurement: Clinic.